Aneesha Shetty

Interests

No activities entered.

Courses

No activities entered.

Scholarly Contributions

Journals/Publications

• Durand, C. M., Martinez, N., Neumann, K., Benedict, R. C., Baker, A. W., Wolfe, C. R., Stosor, V., Shetty, A., Dietch, Z. C., Goudy, L., Callegari, M. A., Massie, A. B., Brown, D., Cochran, W., Muzaale, A., Fine, D., Tobian, A. A., Winkler, C. A., Al Ammary, F., , Segev, D. L., et al. (2023). Living kidney donors with HIV: experience and outcomes from a case series by the HOPE in Action Consortium. Lancet regional health. Americas, 24, 100553.
  More info

  Living kidney donation is possible for people living with HIV (PLWH) in the United States within research studies under the HIV Organ Policy Equity (HOPE) Act. There are concerns that donor nephrectomy may have an increased risk of end-stage renal disease (ESRD) in PLWH due to HIV-associated kidney disease and antiretroviral therapy (ART) nephrotoxicity. Here we report the first 3 cases of living kidney donors with HIV under the HOPE Act in the United States.
• Smith, J. D., Agrawal, A., Wicklund, C., Duquette, D., Friedewald, J., Rasmussen, L. V., Gacki-Smith, J., Tandon, S. D., Muhammad, L. N., Yancy, C. W., Dong, S., Cooper, M., Gilbert, A., Shetty, A., & Gordon, E. J. (2023). Implementation of a culturally competent genetic testing programme into living donor evaluation: A two-site, non-randomised, pre-post trial design. BMJ open, 13(5), e067657.
  More info

  While living donor (LD) kidney transplantation is the optimal treatment for patients with kidney failure, LDs assume a higher risk of future kidney failure themselves. LDs of African ancestry have an even greater risk of kidney failure post-donation than White LDs. Because evidence suggests that Apolipoprotein L1 () risk variants contribute to this greater risk, transplant nephrologists are increasingly using genetic testing to evaluate LD candidates of African ancestry. However, nephrologists do not consistently perform genetic counselling with LD candidates about due to a lack of knowledge and skill in counselling. Without proper counselling, testing will magnify LD candidates' decisional conflict about donating, jeopardising their informed consent. Given cultural concerns about genetic testing among people of African ancestry, protecting LD candidates' safety is essential to improve informed decisions about donating. Clinical 'chatbots', mobile apps that provide genetic information to patients, can improve informed treatment decisions. No chatbot on is available and no nephrologist training programmes are available to provide culturally competent counselling to LDs about . Given the shortage of genetic counsellors, increasing nephrologists' genetic literacy is critical to integrating genetic testing into practice.
• Sridhara, S., Gungor, A. B., Erol, H. K., Al-Obaidi, M., Zangeneh, T. T., Bedrick, E. J., Ariyamuthu, V. K., Shetty, A., Qannus, A. A., Mendoza, K., Murugapandian, S., Gupta, G., & Tanriover, B. (2023). Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era. PloS one, 18(4), e0279326.
  More info

  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real-world experience regarding its effectiveness is scarce. This retrospective cohort study reports a data analysis in Banner Healthcare System (a large not-for-profit organization) between 4/5/2022 and 8/1/2022 and included 19,778 Coronavirus disease-19 (COVID-19) positive (by PCR or direct antigen testing) patients who were selected from Cerner-Electronic Health Record after the exclusions criteria were met. The study index date for cohort was determined as the date of BEB MAb administration or the date of the first positive COVID-19 testing. The cohort consist of COVID-19 infected patients who received BEB MAb (N = 1,091) compared to propensity score (PS) matched control (N = 1,091). The primary composite outcome was the incidence of 30-day all-cause hospitalization and/or mortality. All statistical analyses were conducted on the paired (matched) dataset. For the primary composite outcome, the event counts and percentages were reported. Ninety-five percent Clopper-Pearson confidence intervals for percentages were computed. The study cohorts were 1:1 propensity matched without replacement across 26 covariates using an optimal matching algorithm that minimizes the sum of absolute pairwise distance across the matched sample after fitting and using logistic regression as the distance function. The pairs were matched exactly on patient vaccination status, BMI group, age group and diabetes status. Compared to the PS matched control group (2.6%; 95% confidence interval [CI]: 1.7%, 3.7%), BEB MAb use (2.2%; 95% CI: 1.4%, 3.3%) did not significantly reduce the incidence of the primary outcome (p = 0.67). In the subgroup analysis, we observed similar no-difference trends regarding the primary outcomes for the propensity rematched BEB MAb treated and untreated groups, stratified by patient vaccination status, age (
• Shetty, A., Hod‐Dvorai, R., Lee, R., Muluhngwi, P., Raijmakers, M., Tambur, A., & Ison, M. (2022). Development of de novo donor specific antibodies in renal transplant recipients with BK viremia managed with immunosuppression reduction. Transplant Infectious Disease.
• Shetty, A., Smith, K., Ali, S., Stosor, V., Vorovich, E., & Sustento-Reodica, N. (2022).
  BK Virus Nephropathy in HIV-Positive Heart-Kidney Transplant Recipient. The Journal of Heart and Lung Transplantation.
• Tanriover, B., Anand, P. M., Ayvaci, M., Murugapandian, S., Qannus, A. A., Shetty, A., ARIYAMUTHU, V. K., Heise, C. W., Rangan, P., Alam, R., Nicole, A., Johnson, K., Bedrick, E. J., Zangeneh, T. T., Nematollahi, S., Gungor, A. b., & Al-Obaidi, M. (2022).

  Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection

  . Open forum infectious diseases.
• Sherrid, M. V., Shetty, A., Winson, G., Kim, B., Musat, D., Alviar, C. L., Homel, P., Balaram, S. K., & Swistel, D. G. (2013). Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil.. Circulation. Heart failure, 6(4), 694-702. doi:10.1161/circheartfailure.112.000122
  More info

  There is controversy about preferred methods to relieve obstruction in hypertrophic cardiomyopathy patients still symptomatic after β-blockade or verapamil..Of 737 patients prospectively registered at our institution, 299 (41%) required further therapy for obstruction for limiting symptoms, rest gradient 61 ± 45, provoked gradient 115 ± 49 mm Hg, and followed up for 4.8 years. Disopyramide was added in 221 (74%) patients and pharmacological control of symptoms was achieved in 141 (64%) patients. Overall, 138 (46%) patients had surgical relief of obstruction (91% myectomy) and 6 (2%) alcohol septal ablation. At follow-up, resting gradients in the 299 patients had decreased from 61 ± 44 to 10 ± 25 mm Hg (P

Presentations

• Shetty, A. (2023). AKi and cirrhosis. Hepatology Conference, Division of Gastroenterology and Hepatology, Northwestern Medicine, Chicago.
• Shetty, A. (2023). Long term follow-up of Living Kidney Donors. Kidney Week 2023American Society of Nephrology.
• Shetty, A. (2023). Pre-emptive Kidney Transplantation. Southwest Nephrology Conference, hosted by National Kidney Foundation of ArizonaNational Kidney Foundation of Arizona.

Reviews

• Shetty, A., Ariyamuthu, V. K., Gungor, A. B., & Tanriover, B. (2023. Utilization of hepatitis C virus-positive donors in kidney transplantation(pp 22-28).
  More info

  Direct-acting antivirals (DAA) have transformed kidney transplantation by increasing the donor pool from hepatitis C virus (HCV)-infected donors and allowing HCV nucleic acid amplification testing (NAT) donor-positive/recipient-negative (D+/R-) transplantation over the last 7 years. Willingness to accept kidneys from HCV-infected donors and timing/duration of DAA therapy have been evolving.